We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




New Test Detects Early-Stage Solid Tumors Using Only Blood Sample

By LabMedica International staff writers
Posted on 05 Aug 2025

Current methods for cancer diagnosis largely depend on identifying biomarkers—molecules that reflect a biological state—produced by tumors or associated proteins. More...

However, these markers tend to become more detectable only when the tumor has significantly developed, making early detection difficult. This delay complicates treatment, as advanced-stage tumors are harder to manage effectively. Although immune system changes during the early stages of cancer have been known for over a century, they have not been utilized for diagnosis until now. Now, a new test targets these early immune disruptions in blood proteins to detect tumors at their earliest stages and even offers insight into a patient’s potential response to treatment.

This innovative test, developed by researchers at the Spanish National Cancer Research Centre (CNIO, Madrid, Spain), with support from the University of Cambridge (Cambridge, UK) and other institutions, aims to detect early-stage tumors with a blood sample. Instead of focusing on tumor-produced biomarkers, the researchers examined the body's immune response to cancer, specifically alterations in blood proteins caused by immune system disruption. Given the complexity of human plasma, which contains more than 5,000 proteins, the team narrowed their study to five amino acids: lysine, tryptophan, tyrosine, cysteine, and non-disulphide bonded cysteine. Fluorogenic reactions were applied to reveal the concentration of these amino acids, and machine learning algorithms were used to detect diagnostic patterns in the data. The test is simple to administer, requiring only a small blood sample and hospital-available reagents. The team is also developing a platform that will automate data analysis to facilitate diagnosis. Importantly, the test can differentiate cancer from other conditions such as COVID-19 and distinguish between different cancer types and stages, offering valuable information for clinical decision-making.

The test was evaluated using blood samples from 170 individuals, correctly identifying 78% of cancers with a 0% false-positive rate. The results, published in Nature Communications, showed that the test also predicted with 100% accuracy which patients would not respond to anti-metastatic treatment, and 87% accuracy in predicting responders, supporting its utility in precision medicine. Researchers highlight that the test's application extends beyond diagnosis to predicting treatment response, aiding personalized care. Although the current sample size has provided promising outcomes, larger datasets are needed to commercialize the platform. To address this, clinical trials are already underway in the UK, while other studies are ongoing in the US and China.

"Our approach has proven particularly effective in detecting tumors at an early stage, which is crucial because, if we detect them early, we can treat many types of cancer," said Gonçalo Bernardes, lead investigator of the study. ‘It is very important to note that by analyzing samples from patients with other diseases, we have found that the signals are different. For example, the immune signals of a person with SARS-CoV are different from the signals of a person with cancer, as are the signals of different types of cancer and even cancer in its different stages. We can identify all of that with our test.”

Related Links:
CNIO
University of Cambridge


Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Sperm Quality Analyis Kit
QwikCheck Beads Precision and Linearity Kit
New
Silver Member
Quality Control Material
NATtrol Chlamydia trachomatis Positive Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: The microfluidic device for passive separation of platelet-rich plasma from whole blood (Photo courtesy of University of the Basque Country)

Portable and Disposable Device Obtains Platelet-Rich Plasma Without Complex Equipment

Platelet-rich plasma (PRP) plays a crucial role in regenerative medicine due to its ability to accelerate healing and repair tissue. However, obtaining PRP traditionally requires expensive centrifugation... Read more

Immunology

view channel
Image: PD-1 protein blockade is the standard treatment for advanced melanoma among the different types of immunotherapy (Photo courtesy of 123RF)

Precision Tool Predicts Immunotherapy Treatment Failure in Melanoma Patients

Melanoma, though accounting for only about 4% of skin tumors, is the deadliest form of skin cancer due to its high potential to metastasize. While immunotherapy, especially PD-1 protein blockade, has revolutionized... Read more

Pathology

view channel
Image: Genai-based pathological assessment workflow for lung adenocarcinoma (Shen J. et al., Int J Surg 111(7): 4252–4262; 2025)

Generative AI Demonstrates Expert-Level Pathological Assessment of Lung Cancer

Lung adenocarcinoma is one of the most difficult cancers to diagnose accurately, requiring pathologists to spend extensive time examining tissue samples under microscopes to determine tumor grades and... Read more

Industry

view channel
Image: Alzheimer’s Association has released its first clinical practice guideline for blood-based biomarker tests (Photo courtesy of Alzheimer’s Association)

New Clinical Guidelines Recommend Use of Blood Tests Instead of Brain Scans for Alzheimer’s Diagnosis

Alzheimer’s disease is a progressive neurodegenerative condition that remains challenging to diagnose early and accurately, particularly in individuals with cognitive impairment. Despite the availability... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.